NeuroOne reports preliminary FY2025 product revenue of $9.1M, up 163% from $3.5M in FY2024

NEUROONE MEDICAL TECHNOLOGIES Corp

2025-FY EPS reported -$0.09 revenue$9,097,692

Preliminary unaudited FY2025 product revenue $9.1M, a record; FY2024 was $3.5M.
Cash and equivalents $6.6M as of September 30, 2025.
Growth driven by expanded customer interest in OneRF Ablation system for epilepsy.
Complete financial results expected to be announced in December 2025.
Company to host virtual investor webinar on October 7, 2025 at 8:30am EST.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.